Related Experiment Video
Updated: Mar 23, 2026

Murine Precision-Cut Liver Slices as an Ex Vivo Model of Liver Biology
Published on: March 14, 2020
PNPLA3 gene in liver diseases
Eric Trépo1, Stefano Romeo2, Jessica Zucman-Rossi3
1Inserm, UMR-1162, Génomique Fonctionnelle des Tumeurs Solides, Equipe Labellisée Ligue Contre le Cancer, Institut Universitaire d'Hématologie, Paris, France; Department of Gastroenterology, Hepatopancreatology, and Digestive Oncology, CUB Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium; Laboratory of Experimental Gastroenterology, Université Libre de Bruxelles, Brussels, Belgium.
A specific gene variant (rs738409 C>G p.I148M) in patatin-like phospholipase domain containing 3 (PNPLA3) is strongly linked to nonalcoholic fatty liver disease and its progression. Understanding liver fat metabolism is crucial for predicting liver disease outcomes.
Area of Science:
- Genetics
- Hepatology
- Molecular Biology
Background:
- Genome-wide association studies (GWAS) have identified genetic loci associated with liver diseases.
- A 2008 GWAS linked the PNPLA3 gene variant rs738409 (I148M) to nonalcoholic fatty liver disease (NAFLD).
- This variant is also associated with hepatic steatosis, fibrosis, cirrhosis, and hepatocellular carcinoma across various liver insults.
Purpose of the Study:
- To investigate the role of the PNPLA3 gene variant in liver disease pathophysiology.
- To explore the impact of liver fat metabolism on liver disease progression.
- To assess the predictive value of genetic variants for liver disease outcomes.
Main Methods:
- Genome-wide association studies (GWAS) and replication studies.
- Measurement of hepatic liver fat content using magnetic resonance spectroscopy.
- Functional studies of PNPLA3 protein lipase activity.
Main Results:
- The PNPLA3 I148M variant significantly associates with increased triglyceride accumulation in hepatocytes due to impaired lipase activity.
- This genetic factor contributes to the development and progression of various liver conditions, including NAFLD, fibrosis, and hepatocellular carcinoma.
- While significant, the PNPLA3 locus alone has limited predictive power for clinical outcomes.
Conclusions:
- Liver fat metabolism, influenced by genetic factors like PNPLA3, plays a critical role in liver disease pathogenesis.
- Further GWAS are needed to identify additional variants contributing to liver damage and cancer.
- Integrating genetic data with clinical information may enable personalized predictive models for liver disease management.
Related Concept Videos
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Cell Specific Gene Expression
Pharmacogenomics: Identification of New Drug Targets
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...

